Bufalin Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Macrophage Pyroptosis via P62 Pathway
Journal of Cardiovascular Translational Research · 2025-04 · 18 (2) · 221-236
DOI: 10.1007/s12265-024-10577-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Translational Research, online erschienen am 28.12.2024. Verfasst von Chang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Pyroptosis, Myocardial Reperfusion Injury, Bufanolides, Myocytes, Cardiac. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bufalin, which is isolated from toad venom, exerts positive effects on hearts under pathological circumstance. We aimed to investigate the effects and mechanisms of bufalin on myocardial I/R injury. In vivo, bufalin ameliorated myocardial I/R injury, which characteristics with better ejection function, decreased infarct size and less apoptosis. The levels of pyroptotic proteins were increased in I/R-treated macrophages and inflammatory cytokines expressed more in I/R-induced mouse, which could be attenuated by bufalin. Bufalin also reduced H/R-treated macrophage pyroptosis in vitro. Autophagic flux blockage and ROS accumulation were reduced by bufalin in impaired macrophages. Overexpression of p62 abrogated the anti-proptosis and anti-oxidative effects of bufalin. The levels of apoptosis related proteins were changed and TUNEL-positive ratio was raised in cardiomyocytes that received conditioned medium treatment with H/R-treated macrophages, while bufalin pretreatment could reduce apoptosis. These findings indicate that bufalin may attenuate myocardial I/R injury by suppressing macrophage pyroptosis via P62 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
- Institutes of Biomedical Sciences, Fudan University, 131 Dong'an Road, Shanghai, 200032, China.
- Department of Cardiology, Shanghai Fifth People's Hospital, Fudan University, 128 Ruili Road, Shanghai, 200032, China.
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zhiwen_d@fudan.edu.cn.
- Institutes of Biomedical Sciences, Fudan University, 131 Dong'an Road, Shanghai, 200032, China. zhiwen_d@fudan.edu.cn.
- Department of Cardiac Surgery, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. yang.cheng@zs-hospital.sh.cn.
ORCID-Profile: Yunzeng Zou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, C., Ma, Z., Wei, X., Wang, Y., Wu, J., Li, X., Sun, X., Ding, Z., Yang, C., & Zou, Y. (2025). Bufalin Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Macrophage Pyroptosis via P62 Pathway. Journal of Cardiovascular Translational Research, 18(2), 221-236. https://doi.org/10.1007/s12265-024-10577-9
Vancouver
Li C, Ma Z, Wei X, Wang Y, Wu J, Li X, et al. Bufalin Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Macrophage Pyroptosis via P62 Pathway. Journal of Cardiovascular Translational Research. 2025;18(2):221-236. doi:10.1007/s12265-024-10577-9
BibTeX
@article{Li2025,
author = {Li, Chang and Ma, Zhen and Wei, Xiang and Wang, Ying and Wu, Jian and Li, Xuan and Sun, Xiaolei and Ding, Zhiwen and Yang, Cheng and Zou, Yunzeng},
title = {Bufalin Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Macrophage Pyroptosis via P62 Pathway},
journal = {Journal of Cardiovascular Translational Research},
year = {2025},
volume = {18},
number = {2},
pages = {221--236},
doi = {10.1007/s12265-024-10577-9}
}
EUVIMED